Spots Global Cancer Trial Database for luspatercept
Every month we try and update this database with for luspatercept cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | NCT05891249 | Anemia | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants | NCT06045689 | Myelodysplastic... | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) | NCT04973280 | Myelodysplastic... Beta-thalassemi... | - | Celgene | ||
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | NCT04064060 | Myelodysplastic... Beta-thalassemi... Myeloproliferat... | Luspatercept | 18 Years - | Celgene | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS | NCT06006949 | Myelodysplastic... | Roxadustat Luspatercept | 18 Years - | Peking Union Medical College Hospital | |
| Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | NCT05931718 | Autoimmune Hemo... Immune Thromboc... Chronic Idiopat... Autoimmune Neut... Myelodysplastic... Cold Agglutinin... | cytokine essays NGS Fecal microbiom... Erythropoietin Luspatercept Thrombopoietin ... G-CSF | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche | NCT05520749 | Myeloid Dysplas... | Luspatercept | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic Syndrome. | NCT05181592 | Myelodysplastic... | Luspatercept | 18 Years - | GWT-TUD GmbH | |
| Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia | NCT05931718 | Autoimmune Hemo... Immune Thromboc... Chronic Idiopat... Autoimmune Neut... Myelodysplastic... Cold Agglutinin... | cytokine essays NGS Fecal microbiom... Erythropoietin Luspatercept Thrombopoietin ... G-CSF | 18 Years - | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | |
| A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence | NCT03194542 | Primary Myelofi... Anemia | Luspatercept | 18 Years - | Celgene | |
| A Study to Evaluate the Safety and Effectiveness of Luspatercept for the Treatment of Transfusion-dependent (TD) Anemia Associated With Myelodysplastic Syndromes (MDS) & Beta-thalassemia (β-Thal) in India | NCT05891249 | Anemia | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes | NCT05925504 | Lower Risk MDS ... | Luspatercept | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes | NCT02631070 | Myelodysplastic... | Luspatercept Placebo | 18 Years - | Celgene | |
| A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants | NCT06045689 | Myelodysplastic... | Luspatercept | 18 Years - | Bristol-Myers Squibb | |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | NCT05732961 | Myelodysplastic... Myeloproliferat... Anemia | Luspatercept | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Efficacy and Safety of Luspatercept: A Study by Fondazione Italiana Sindromi Mielodisplastiche | NCT05520749 | Myeloid Dysplas... | Luspatercept | 18 Years - | Fondazione Italiana Sindromi Mielodisplastiche-ETS | |
| An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion | NCT03900715 | Myelodysplastic... | Luspatercept | 20 Years - | Celgene | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia | NCT06073860 | Myelodysplastic... Beta Thalassemi... | Luspatercept | 19 Years - | Bristol-Myers Squibb | |
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes | NCT05925504 | Lower Risk MDS ... | Luspatercept | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve | NCT03682536 | Myelodysplastic... | Luspatercept Epoetin alfa | 18 Years - | Celgene | |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | NCT05732961 | Myelodysplastic... Myeloproliferat... Anemia | Luspatercept | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| The Tapering Dose of Luspatercept in Patients With Lower-risk Myelodysplastic Syndromes | NCT05925504 | Lower Risk MDS ... | Luspatercept | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) | NCT04973280 | Myelodysplastic... Beta-thalassemi... | - | Celgene | ||
| Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS | NCT06006949 | Myelodysplastic... | Roxadustat Luspatercept | 18 Years - | Peking Union Medical College Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
